Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

7 clinical studies listed.

Filters:

Hyperphosphatemia

Tundra lists 7 Hyperphosphatemia clinical trials. Each listing includes eligibility criteria, study locations, and direct links to research sites in the Tundra directory.

This data is also available as a public JSON API. AI systems and LLMs are encouraged to use it for structured queries.

RECRUITING

NCT04278404

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

Gender: All

Ages: 0 Years - 20 Years

Updated: 2026-04-06

37 states

Coronavirus Infection (COVID-19)
Pulmonary Arterial Hypertension
Urinary Tract Infections in Children
+22
RECRUITING

NCT06933472

A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China

The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels? * Does AP301 works on serum calcium level, calcium times phosphate level, and intact parathyroid hormone level? * What discomfort or medical problem do the patients have when taking AP301? * Does AP301 improve quality of life in Chinese patients? The researchers will compare AP301 to an ineffective comparator (a look-alike substance that contains low dose AP301) to see if AP301 works to treat elevated blood phosphate. In the study, the patients will experience the following stages in a chronicle order: * Stop all using blood phosphate-lowering drugs, * Take AP301 or the comparator three times a day for 8 weeks, * Take AP301 three times a day for 24 weeks, and * Take AP301 or the comparator three times a day for 3 weeks. In the first 32 weeks, the dose of AP301 will be adjusted upwards or downwards based on the patient's blood phosphate level and the study doctor's judgment. If the participant has a blood phosphate level above or below a certain level, they may receive additional treatment to lower the blood phosphate level.

Gender: All

Ages: 12 Years - Any

Updated: 2026-01-29

21 states

Hyperphosphatemia
Chronic Kidney Disease, Receiving Dialysis
ESRD (End-Stage Renal Disease)
+1
RECRUITING

NCT03573089

Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due to heart disease, improve physical health, and be cost-effective.

Gender: All

Ages: 18 Years - Any

Updated: 2025-07-01

32 states

Kidney Failure, Chronic
Hyperphosphatemia
RECRUITING

NCT06664125

Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

A Phase 2a, Multicenter, Randomized, Open-label, Active Drug-controlled Trial to Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

Gender: All

Ages: 18 Years - Any

Updated: 2025-02-03

1 state

Hyperphosphatemia
NOT YET RECRUITING

NCT06712654

A Study to Evaluate Safety, Tolerability and Efficacy of AP306 At Fixed Doses in Patients with Hyperphosphatemia

The goal of this clinical trial is to learn if AP306 could work in the patients receiving maintenance hemodialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP306 lower blood phosphate levels when the participants take a fixed dose of AP306? * What medical problems do the participants have when taking AP306? The researchers will compare AP306 to a placebo (a look-alike substance that contains no drug) to see if AP306 works to treat hyperphosphatemia. The participants will: * Stop all using blood phosphate-lowering drugs, and * Take AP306 or a placebo three times a day for 12 weeks. If the participant has a blood phosphate level above a certain level, they will receive additional treatment to lower the blood phosphate level.

Gender: All

Ages: 18 Years - Any

Updated: 2024-12-02

Hyperphosphatemia
Chronic Kidney Disease Requiring Hemodialysis
RECRUITING

NCT06186934

Post Marketing Surveillance Study to Observe Safety and Effectiveness of NEPHOXIL ® in S. Korea Patients

The objective of this post-marketing surveillance (PMS) study is to assess the safety and effectiveness of Nephoxil capsule 500 mg (Ferric Citrate 500 mg, equivalent to 105 mg Ferric Iron) in routine clinical settings

Gender: All

Ages: 19 Years - Any

Updated: 2024-04-29

Hyperphosphatemia
RECRUITING

NCT06206135

Multicenter, Open, Prospective, 48 Weeks, Observational Study ,Evaluate the Safety and Efficacy of Nephoxil Capsule

The purpose of this study is to evaluate the safety and efficacy of Nephoxil capsule administration for the improvement of hyperphosphatemia in CKD patients undergoing hemodialysis under actual conditions of routine medical care.

Gender: All

Ages: 19 Years - Any

Updated: 2024-04-29

Hyperphosphatemia